Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/09/009841
CTRI/2017/09/009841
Completed
未知

An Experimental Preventive trial for the assessment of non-pharmacological intervention in the management of Hypertension in a tertiary care centre of metropolitan city.

Dr Rujuta Hadaye0 sites150 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: I10- Essential (primary) hypertensionHealth Condition 2: null- Hypertension

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: I10- Essential (primary) hypertensionHealth Condition 2: null- Hypertension
Sponsor
Dr Rujuta Hadaye
Enrollment
150
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 31, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Rujuta Hadaye

Eligibility Criteria

Inclusion Criteria

  • •all patients with pre hypertension and stage 1 hypertension will be included

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Effect of pilocarpin on xerostomialarynx, Hypopharynx, Nasopharynx.Malignant neoplasm of larynx, Malignant neoplasm of hypopharynx, Malignant of nasopharynxc11?c13?c3
IRCT2014042013167N2Shahid Sadoughi University of Medical Sciences34
Completed
Not Applicable
A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infectiorinary tract infection
JPRN-UMIN000007232Workshop of urinary tract infection300
Completed
Not Applicable
A clinical study to evaluate the preventive effect of denosumab(Pralia) on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
JPRN-UMIN000015127Department of Urology, Keio University School of Medicine40
Recruiting
Phase 1
A prospective controlled trial to evaluate safety and efficacy of in vitro expanded recipient regulatory T cell therapy and tocilizumab together with donor bone marrow infusion in HLA-mismatched living donor kidney transplant recipients (Trex)Kidney transplantationMedDRA version: 20.0Level: LLTClassification code: 10023438Term: Kidney transplant Class: 10042613Therapeutic area: Diseases [C] - Immune System Diseases [C20]
CTIS2024-513459-34-00Medical University Of Vienna24
Active, not recruiting
Phase 1/2
A prospective controlled trial to evaluate safety and efficacy of in vitro expanded recipient regulatory T cell therapy and tocilizumab together with donor bone marrow infusion in HLA-mismatched living donor kidney transplant recipients (Trex)
2024-513459-34-00Medical University Of Vienna24